{
    "info": {
        "nct_id": "NCT03486314",
        "official_title": "A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients With Advanced Solid Tumors",
        "inclusion_criteria": "1. Adult participants who have a histologically or cytologically confirmed metastatic or locally advanced solid tumor that is appropriate for treatment with either docetaxel or carboplatin + paclitaxel in Part B of this study, or have progressed despite standard therapy, or for whom conventional therapy is not considered effective.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n3. Expected survival of at least 3 months from the date of enrollment in the study.\n4. Recovered (that is, less than or equal to (<=) Grade 1 toxicity) from the effects of prior antineoplastic therapy.\n5. Adequate organ functions (kidney, liver, cardiac, bone marrow).\n6. Suitable venous access for the study-required blood sampling (including PK sampling).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Prior treatment with radiation therapy involving greater than or equal to (>=) 25% of the hematopoietically active bone marrow.\n2. Life-threatening illness or serious (acute or chronic) medical or psychiatric illness unrelated to cancer.\n3. Active, uncontrolled infection or severe infectious disease.\n4. Known human immunodeficiency virus (HIV) seropositive or known hepatitis B or hepatitis C infection.\n5. With significant heart or pulmonary disease.\n6. Requiring chronic treatment with breast cancer resistance protein (BCRP) inhibitors.\n\nCriteria for Continuation into Optional Part B:\n\nTo be eligible for Part B, participants must have completed Part A and be reassessed to determine if they meet the continuation criteria for Part B.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Expected survival of at least 3 months from the date of enrollment in the study.",
            "criterions": [
                {
                    "exact_snippets": "Expected survival of at least 3 months",
                    "criterion": "expected survival",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Recovered (that is, less than or equal to (<=) Grade 1 toxicity) from the effects of prior antineoplastic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Recovered (that is, less than or equal to (<=) Grade 1 toxicity) from the effects of prior antineoplastic therapy.",
                    "criterion": "toxicity from prior antineoplastic therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Adult participants who have a histologically or cytologically confirmed metastatic or locally advanced solid tumor that is appropriate for treatment with either docetaxel or carboplatin + paclitaxel in Part B of this study, or have progressed despite standard therapy, or for whom conventional therapy is not considered effective.",
            "criterions": [
                {
                    "exact_snippets": "Adult participants",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "histologically or cytologically confirmed metastatic or locally advanced solid tumor",
                    "criterion": "solid tumor diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "metastatic",
                                "locally advanced"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "appropriate for treatment with either docetaxel or carboplatin + paclitaxel in Part B of this study",
                    "criterion": "tumor suitability for treatment",
                    "requirements": [
                        {
                            "requirement_type": "appropriate for treatment",
                            "expected_value": [
                                "docetaxel",
                                "carboplatin + paclitaxel"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have progressed despite standard therapy",
                    "criterion": "disease progression after standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression after standard therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for whom conventional therapy is not considered effective",
                    "criterion": "effectiveness of conventional therapy",
                    "requirements": [
                        {
                            "requirement_type": "conventional therapy effectiveness",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Suitable venous access for the study-required blood sampling (including PK sampling).",
            "criterions": [
                {
                    "exact_snippets": "Suitable venous access for the study-required blood sampling (including PK sampling)",
                    "criterion": "venous access",
                    "requirements": [
                        {
                            "requirement_type": "suitability for blood sampling",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Adequate organ functions (kidney, liver, cardiac, bone marrow).",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ functions (kidney",
                    "criterion": "kidney function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ functions ... liver",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ functions ... cardiac",
                    "criterion": "cardiac function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ functions ... bone marrow",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "5. With significant heart or pulmonary disease.",
            "criterions": [
                {
                    "exact_snippets": "significant heart ... disease",
                    "criterion": "heart disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "significant ... pulmonary disease",
                    "criterion": "pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Prior treatment with radiation therapy involving greater than or equal to (>=) 25% of the hematopoietically active bone marrow.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with radiation therapy involving greater than or equal to (>=) 25% of the hematopoietically active bone marrow.",
                    "criterion": "prior radiation therapy to hematopoietically active bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "extent of involvement",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "hematopoietically active bone marrow"
                        }
                    ]
                }
            ]
        },
        {
            "line": "To be eligible for Part B, participants must have completed Part A and be reassessed to determine if they meet the continuation criteria for Part B.",
            "criterions": [
                {
                    "exact_snippets": "must have completed Part A",
                    "criterion": "completion of Part A",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be reassessed to determine if they meet the continuation criteria for Part B",
                    "criterion": "continuation criteria for Part B",
                    "requirements": [
                        {
                            "requirement_type": "meets continuation criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Known human immunodeficiency virus (HIV) seropositive or known hepatitis B or hepatitis C infection.",
            "criterions": [
                {
                    "exact_snippets": "Known human immunodeficiency virus (HIV) seropositive",
                    "criterion": "HIV seropositivity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known hepatitis B ... infection",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known ... hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Active, uncontrolled infection or severe infectious disease.",
            "criterions": [
                {
                    "exact_snippets": "Active, uncontrolled infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "severe infectious disease",
                    "criterion": "infectious disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Life-threatening illness or serious (acute or chronic) medical or psychiatric illness unrelated to cancer.",
            "criterions": [
                {
                    "exact_snippets": "Life-threatening illness",
                    "criterion": "life-threatening illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "relation to cancer",
                            "expected_value": "unrelated"
                        }
                    ]
                },
                {
                    "exact_snippets": "serious (acute or chronic) medical ... illness unrelated to cancer",
                    "criterion": "serious medical illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "relation to cancer",
                            "expected_value": "unrelated"
                        }
                    ]
                },
                {
                    "exact_snippets": "serious (acute or chronic) ... psychiatric illness unrelated to cancer",
                    "criterion": "serious psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "relation to cancer",
                            "expected_value": "unrelated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Requiring chronic treatment with breast cancer resistance protein (BCRP) inhibitors.",
            "criterions": [
                {
                    "exact_snippets": "Requiring chronic treatment with breast cancer resistance protein (BCRP) inhibitors",
                    "criterion": "chronic treatment with BCRP inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "Criteria for Continuation into Optional Part B:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}